CD274 and non-small cell lung carcinoma: In contrast to our real-world findings, a recent network meta-analysis comparing first-line immune checkpoint inhibitor monotherapies in advanced NSCLC patients with PD-L1 expression ≥50% suggested that cemiplimab may offer superior efficacy over pembrolizumab in terms of PFS and ORR, with comparable OS and no significant differences in safety profiles [13].